Last reviewed · How we verify
NCT05990998
A Head-to-head Comparison of [68Ga]Ga-FAPI and [68Ga]Ga-TATE PET/CT in Patients With Nasopharyngeal Carcinoma: a Single-center, Prospective Study
Phase 1, PHASE2 trial testing 68Ga-DOTATATE and 68Ga-FAPI in Tumor Positron-Emission Tomography in 38 participants. Completed in 1 September 2023.
31 August 2023
Quick facts
| Lead sponsor | First Affiliated Hospital of Fujian Medical University |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 38 |
| Start date | 20 November 2022 |
| Primary completion | 31 August 2023 |
| Estimated completion | 1 September 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- 68Ga-DOTATATE and 68Ga-FAPI — full drug profile →
Conditions studied
- Tumor Positron-Emission Tomography — all drugs for Tumor Positron-Emission Tomography →
Sponsor
First Affiliated Hospital of Fujian Medical University
Who can join
Adults 18 to 80, any sex, with Tumor Positron-Emission Tomography. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Both fibroblast activation protein (FAP)-targeted imaging and somatostatin receptors (SSTR)-targeted imaging were the promising imaging modalities for the diagnosis of primary and metastatic nasopharyngeal carcinoma (NPC). This prospective study is going to investigate to compare the diagnostic efficacy of 68Ga-FAPI and 68Ga-DOTATATE in detecting primary and metastatic NPC lesions, thereby obtaining a more accurate examination method of NPC.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05990998
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other First Affiliated Hospital of Fujian Medical University trials
Trials by the same sponsor.
- NCT07513844 — Optimizing Parameters of Low-Intensity Focused Ultrasound for Pallidal Modulation in Huntington's Disease · NA · not yet recruiting
- NCT07337772 — Comparing Different Doses of Corticosteroids in Local Infiltration Analgesia (LIA) for Total Knee Arthroplasty · NA · recruiting
- NCT07369401 — Deep Brain Stimulation of the Nucleus Accumbens and Anterior Limb of the Internal Capsule in the Treatment of Refractory · NA · not yet recruiting
- NCT07378358 — Evaluation of AI Large Models for Diagnosis and Treatment in Real-World Cases: Multicenter Retrospective Study · recruiting
- NCT07363382 — The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05990998 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Fujian Medical University
- Last refreshed: 26 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05990998.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing